nemtabrutinib (MK-1026) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   135 News 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nemtabrutinib (MK-1026) / Merck (MSD)
BELLWAVE-011, NCT06136559: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/)

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Nemtabrutinib, MK-1026, ARQ 531, Ibrutinib, Acalabrutinib
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
09/32
09/32
BELLWAVE-008, NCT05624554: A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, )

Active, not recruiting
3
300
Europe, US, RoW
Nemtabrutinib, MK-1026, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, RITUXAN®/MabThera, Truxima, Rituximab biosimilar, Ruxience, Riabni
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/27
03/31
BELLWAVE-010, NCT05947851: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/).

Recruiting
3
720
Europe, Canada, US, RoW
Nemtabrutinib, ARQ 531, MK-1026, Venetoclax, ABT-199, GDC-0199, Rituximab
Merck Sharp & Dohme LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
06/33
06/33
2020-002324-36: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Ongoing
2
450
Europe, RoW
MK-1026, [-], Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
B cell malignancies: Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenstroms macroglobulinemia, Diseases [C] - Cancer [C04]
 
 
2021-004450-36: A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malignancies Estudio para evaluar la seguridad y la eficacia de Zlovertamab Vedotin con o sin Nemtabrutinib y en aldultos con neoplasias malignas de linfocitos B.

Ongoing
2
260
Europe
Zilovertamab Vedotin, Nemtabrutinib, MK-2140, MK-1026, Lyophilisate for solution for infusion, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Aggressive and Indolent B-cell Malignancies neoplasias linfoides B agresivas e indolentes, Phase II Signal Finding Study in B-Cell Malignancies Estudio de fase II de búsqueda de neoplasias linfoides B agresivas e indolentes., Diseases [C] - Cancer [C04]
 
 
NCT06572618: Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Recruiting
2
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Nemtabrutinib, ARQ 531, ARQ-531, ARQ531, Bruton's Tyrosine Kinase Inhibitor ARQ 531, BTK Inhibitor ARQ 531, MK-1026, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
01/27
01/27
NCT06863402: Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Not yet recruiting
2
32
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nemtabrutinib, ARQ 531, ARQ-531, ARQ531, Bruton's Tyrosine Kinase Inhibitor ARQ 531, BTK Inhibitor ARQ 531, MK-1026, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration
Roswell Park Cancer Institute
Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
04/29
04/30
waveLINE-006, NCT05458297 / 2021-004450-36: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Recruiting
2
223
Europe, Canada, Japan, US, RoW
Zilovertamab vedotin, MK-2140, Nemtabrutinib, MK-1026
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
03/27
04/27
BELLWAVE-003, NCT04728893 / 2020-002324-36: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Recruiting
2
490
Europe, Canada, US, RoW
Nemtabrutinib, ARQ 531, MK-1026
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
03/27
03/27
BELLWAVE-001, NCT03162536: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Active, not recruiting
1/2
190
US
Nemtabrutinib, ARQ 531, MK-1026
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
09/25
09/25
MK-1026-016, NCT06772805: A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants

Completed
1
18
US
Nemtabrutinib, MK-1026, ARQ-531
Merck Sharp & Dohme LLC
Healthy
12/23
12/23
MK-1026-014, NCT06698016: A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib

Completed
1
16
US
Nemtabrutinib, MK-1026, ARQ 531, Efavirenz
Merck Sharp & Dohme LLC
Healthy
10/23
10/23
NCT06586671: A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

Completed
1
40
US
Nemtabrutinib, MK-1026, ARQ-531
Merck Sharp & Dohme LLC
Hematological Malignancy
11/23
11/23
MK-1026-017, NCT06772818: A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants

Completed
1
20
US
Nemtabrutinib, MK-1026, ARQ-531
Merck Sharp & Dohme LLC
Healthy
12/23
02/24
MK-1026-013, NCT06688045: A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib

Completed
1
15
US
Nemtabrutinib, MK-1026, ARQ-531, Itraconazole
Merck Sharp & Dohme LLC
Healthy
01/24
01/24
MK-1026-012, NCT06625827: A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants

Completed
1
24
US
Digoxin, Nemtabrutinib, MK-1026, ARQ 531
Merck Sharp & Dohme LLC
Healthy
01/24
01/24
MK-1026-015, NCT06442436: A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment

Recruiting
1
16
US
Nemtabrutinib, MK-1026
Merck Sharp & Dohme LLC
Hepatic Impairment (HI)
08/25
08/25
MK-1026-005, NCT05347225: A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies

Active, not recruiting
1
12
RoW
Nemtabrutinib, MK-1026, ARQ 531
Merck Sharp & Dohme LLC
Hematological Malignancies
04/27
04/27
BELLWAVE-002, NCT05673460: A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Active, not recruiting
1
12
Japan
Nemtabrutinib, MK-1026, ARQ 531
Merck Sharp & Dohme LLC
Mature B-cell Neoplasms
03/26
03/26

Download Options